<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/9B520E8D-05F2-4A18-9EDF-C1503366E9E1"><gtr:id>9B520E8D-05F2-4A18-9EDF-C1503366E9E1</gtr:id><gtr:name>Eli Lilly &amp; Company Ltd</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/D1774113-D5D2-4B7C-A412-66A90FE4B96F"><gtr:id>D1774113-D5D2-4B7C-A412-66A90FE4B96F</gtr:id><gtr:name>University of Cambridge</gtr:name><gtr:address><gtr:line1>Lensfield Road</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:postCode>CB2 1EW</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/D1774113-D5D2-4B7C-A412-66A90FE4B96F"><gtr:id>D1774113-D5D2-4B7C-A412-66A90FE4B96F</gtr:id><gtr:name>University of Cambridge</gtr:name><gtr:department>Psychology</gtr:department><gtr:address><gtr:line1>Lensfield Road</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:postCode>CB2 1EW</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/D1774113-D5D2-4B7C-A412-66A90FE4B96F"><gtr:id>D1774113-D5D2-4B7C-A412-66A90FE4B96F</gtr:id><gtr:name>University of Cambridge</gtr:name><gtr:address><gtr:line1>Lensfield Road</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:postCode>CB2 1EW</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/9B520E8D-05F2-4A18-9EDF-C1503366E9E1"><gtr:id>9B520E8D-05F2-4A18-9EDF-C1503366E9E1</gtr:id><gtr:name>Eli Lilly &amp; Company Ltd</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/E6B4B6FC-3DE6-4AE5-853E-D7F9C76E0B15"><gtr:id>E6B4B6FC-3DE6-4AE5-853E-D7F9C76E0B15</gtr:id><gtr:firstName>Ulrich</gtr:firstName><gtr:surname>Muller</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/4E80443A-E7AA-4216-9492-FC8B1A583B53"><gtr:id>4E80443A-E7AA-4216-9492-FC8B1A583B53</gtr:id><gtr:firstName>Trevor</gtr:firstName><gtr:otherNames>William</gtr:otherNames><gtr:surname>Robbins</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/C354010B-4505-46BC-B12F-30E4E1ECF3EE"><gtr:id>C354010B-4505-46BC-B12F-30E4E1ECF3EE</gtr:id><gtr:firstName>Barbara</gtr:firstName><gtr:otherNames>Jacquelyn</gtr:otherNames><gtr:surname>Sahakian</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/FAAA4B9D-BDC0-4D21-92D9-F4C020942B06"><gtr:id>FAAA4B9D-BDC0-4D21-92D9-F4C020942B06</gtr:id><gtr:firstName>Jonathan</gtr:firstName><gtr:otherNames>H</gtr:otherNames><gtr:surname>Dowson</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/A1BD08DC-BADF-4088-A3EB-679EB4A7873A"><gtr:id>A1BD08DC-BADF-4088-A3EB-679EB4A7873A</gtr:id><gtr:firstName>Andrew</gtr:firstName><gtr:surname>Blackwell</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/8549C8AC-C793-4991-AC77-BAEDF1BBDE25"><gtr:id>8549C8AC-C793-4991-AC77-BAEDF1BBDE25</gtr:id><gtr:firstName>Luke</gtr:firstName><gtr:surname>Clark</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0401099"><gtr:id>E731D7D9-1BF4-4F02-A688-6AC3909D80DF</gtr:id><gtr:title>Pathfinder - Positron Emission Tomography Study of Dopamine Transmission in Attention Deficit Hyperactivity Disorder</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0401099</gtr:grantReference><gtr:abstractText>Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.</gtr:abstractText><gtr:fund><gtr:end>2007-09-30</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2005-04-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>250040</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Eli Lilly &amp; Company Ltd</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Lilly collaboration</gtr:description><gtr:id>F7011EED-93DE-419B-99E8-B403369EFA9E</gtr:id><gtr:impact>NA</gtr:impact><gtr:outcomeId>pCYaKTm417y-1</gtr:outcomeId><gtr:piContribution>We have applied for a follow-up project in collaboration with Lilly that will investigate effects of atomoxetine on attentional deficits and dopamine release using methods that were implemented and developed as part of this pathfinder grant.</gtr:piContribution><gtr:sector>Private</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Cambridge</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Department of Psychology</gtr:department><gtr:description>Munich collaboration (Prof. Kathrin Finke)</gtr:description><gtr:id>CA975E24-42A4-4D2E-9090-9F6B54683D92</gtr:id><gtr:impact>2 publications in Psychopharmacology (Finke et al. 2010) and Journal of Abnormal Psychology (Finke et al. 2011), so far</gtr:impact><gtr:outcomeId>ApZJUt8NLGJ-1</gtr:outcomeId><gtr:partnerContribution>Invitations to lectures and project meetings in Munich, provision of experimental paradigm, data analysis and collaborative paper writing.</gtr:partnerContribution><gtr:piContribution>Joint supervision of Master and PhD students. Collaborative pharmacological study in Cambridge</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>45000</gtr:amountPounds><gtr:country>United States of America</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Gates Cambridge Scholarship (N del Campo)</gtr:description><gtr:end>2009-09-02</gtr:end><gtr:fundingOrg>Bill and Melinda Gates Foundation</gtr:fundingOrg><gtr:id>30AA7988-142E-41A9-8392-A319E050C0C2</gtr:id><gtr:outcomeId>MrPfkT4oZG10</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2006-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>250000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>HEFCE Clinical Senior Lectureship Award (U Muller)</gtr:description><gtr:end>2012-09-02</gtr:end><gtr:fundingOrg>Higher Education Funding Council for England (HEFCE)</gtr:fundingOrg><gtr:id>5ED67A91-F4D2-4451-89F8-01C9D63BC669</gtr:id><gtr:outcomeId>NZDwkHrYHkP0</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2007-10-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>81677C04-D6B4-4E6A-8B64-716F00DB381C</gtr:id><gtr:title>Effects of two dopamine-modulating genes (DAT1 9/10 and COMT Val/Met) on n-back working memory performance in healthy volunteers.</gtr:title><gtr:parentPublicationTitle>Psychological medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bf557214c14e8857f382069dd0cfddaa"><gtr:id>bf557214c14e8857f382069dd0cfddaa</gtr:id><gtr:otherNames>Blanchard MM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0033-2917</gtr:issn><gtr:outcomeId>nLRRnwKdqyX</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D7570C7F-7EC9-4D29-B3D2-C45C4F8969E1</gtr:id><gtr:title>Lack of deleterious effects of buspirone on cognition in healthy male volunteers.</gtr:title><gtr:parentPublicationTitle>Journal of psychopharmacology (Oxford, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bff0bd6dd073ac6f1cc91dda15d6a4ff"><gtr:id>bff0bd6dd073ac6f1cc91dda15d6a4ff</gtr:id><gtr:otherNames>Chamberlain SR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0269-8811</gtr:issn><gtr:outcomeId>RiaFokbpfJy</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DB15EFF7-B2D7-4616-A1E3-CCC3BDCC299D</gtr:id><gtr:title>Evidence for a Long-Lasting Compulsive Alcohol Seeking Phenotype in Rats.</gtr:title><gtr:parentPublicationTitle>Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/973615a89580eaa89cbe368476e4c8b1"><gtr:id>973615a89580eaa89cbe368476e4c8b1</gtr:id><gtr:otherNames>Giuliano C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>0893-133X</gtr:issn><gtr:outcomeId>5a7b0587c681e7.33403694</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>29BC1FDD-82DB-4D1B-A9AD-5A45559D9FA1</gtr:id><gtr:title>A positron emission tomography study of nigro-striatal dopaminergic mechanisms underlying attention: implications for ADHD and its treatment.</gtr:title><gtr:parentPublicationTitle>Brain : a journal of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c78fcb420fc5eb74186d612ccc17959c"><gtr:id>c78fcb420fc5eb74186d612ccc17959c</gtr:id><gtr:otherNames>del Campo N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0006-8950</gtr:issn><gtr:outcomeId>pm_540e13ce13c4dd50b</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9537EB3C-075E-4A7E-A169-B58555175A96</gtr:id><gtr:title>Atomoxetine improved response inhibition in adults with attention deficit/hyperactivity disorder.</gtr:title><gtr:parentPublicationTitle>Biological psychiatry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bff0bd6dd073ac6f1cc91dda15d6a4ff"><gtr:id>bff0bd6dd073ac6f1cc91dda15d6a4ff</gtr:id><gtr:otherNames>Chamberlain SR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0006-3223</gtr:issn><gtr:outcomeId>cR9yX5NMMTS</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DE235FF2-76FD-4F11-9A86-75CD32A63FF3</gtr:id><gtr:title>Neurochemical modulation of response inhibition and probabilistic learning in humans.</gtr:title><gtr:parentPublicationTitle>Science (New York, N.Y.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bff0bd6dd073ac6f1cc91dda15d6a4ff"><gtr:id>bff0bd6dd073ac6f1cc91dda15d6a4ff</gtr:id><gtr:otherNames>Chamberlain SR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0036-8075</gtr:issn><gtr:outcomeId>QEywMPofytk</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3AE0E64C-8368-4225-83DD-2A93E88B7725</gtr:id><gtr:title>Effects of the catechol-O-methyltransferase Val158Met polymorphism on executive function: a meta-analysis of the Wisconsin Card Sort Test in schizophrenia and healthy controls.</gtr:title><gtr:parentPublicationTitle>Molecular psychiatry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/28bbaf5ac24ca5c325644a5872ff483e"><gtr:id>28bbaf5ac24ca5c325644a5872ff483e</gtr:id><gtr:otherNames>Barnett JH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>1359-4184</gtr:issn><gtr:outcomeId>QPaQtjC7yrp</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2D01769A-8828-4B44-9651-99F5932B622F</gtr:id><gtr:title>Atomoxetine modulates right inferior frontal activation during inhibitory control: a pharmacological functional magnetic resonance imaging study.</gtr:title><gtr:parentPublicationTitle>Biological psychiatry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bff0bd6dd073ac6f1cc91dda15d6a4ff"><gtr:id>bff0bd6dd073ac6f1cc91dda15d6a4ff</gtr:id><gtr:otherNames>Chamberlain SR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0006-3223</gtr:issn><gtr:outcomeId>RfrTqDbzavE</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F2C277FD-FB14-48D7-8857-9050F2F75E94</gtr:id><gtr:title>Neuropharmacological modulation of cognition.</gtr:title><gtr:parentPublicationTitle>Current opinion in neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bff0bd6dd073ac6f1cc91dda15d6a4ff"><gtr:id>bff0bd6dd073ac6f1cc91dda15d6a4ff</gtr:id><gtr:otherNames>Chamberlain SR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>1350-7540</gtr:issn><gtr:outcomeId>j1eyu1yVGRt</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6E20BE20-0A75-4A77-A3D1-D7C742175330</gtr:id><gtr:title>Atomoxetine increases salivary cortisol in healthy volunteers.</gtr:title><gtr:parentPublicationTitle>Journal of psychopharmacology (Oxford, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bff0bd6dd073ac6f1cc91dda15d6a4ff"><gtr:id>bff0bd6dd073ac6f1cc91dda15d6a4ff</gtr:id><gtr:otherNames>Chamberlain SR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0269-8811</gtr:issn><gtr:outcomeId>ES8jDPy4JYv</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>14029EA4-E866-4BAC-98B8-31BA2F7E2183</gtr:id><gtr:title>Quantification of receptor-ligand binding potential in sub-striatal domains using probabilistic and template regions of interest.</gtr:title><gtr:parentPublicationTitle>NeuroImage</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c78fcb420fc5eb74186d612ccc17959c"><gtr:id>c78fcb420fc5eb74186d612ccc17959c</gtr:id><gtr:otherNames>del Campo N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1053-8119</gtr:issn><gtr:outcomeId>tiJC7rjM9Qe</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C56E59C4-2F03-475F-A8ED-8316D96AFC7D</gtr:id><gtr:title>Noradrenergic modulation of working memory and emotional memory in humans.</gtr:title><gtr:parentPublicationTitle>Psychopharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bff0bd6dd073ac6f1cc91dda15d6a4ff"><gtr:id>bff0bd6dd073ac6f1cc91dda15d6a4ff</gtr:id><gtr:otherNames>Chamberlain SR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0033-3158</gtr:issn><gtr:outcomeId>omAu5HqXZMw</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6A41F6C8-BF51-4172-9F67-4407505FBBE1</gtr:id><gtr:title>Effects of modafinil and methylphenidate on visual attention capacity: a TVA-based study.</gtr:title><gtr:parentPublicationTitle>Psychopharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/832fc91eeae397936cb184ddaef5e59b"><gtr:id>832fc91eeae397936cb184ddaef5e59b</gtr:id><gtr:otherNames>Finke K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0033-3158</gtr:issn><gtr:outcomeId>fY5BHDZVBrt</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0401099</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>3C193D18-12BD-4B15-8347-037BA623E0FF</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Mental Health</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>